1
|
Vukusic D, Zenko Sever A, Sever M, Drmic D, Milavic M, Sikiric S, Rasic D, Krezic I, Gojkovic S, Prtoric A, Bubalo P, Coric L, Dobric I, Boban Blagaic A, Rasic Z, Skrtic A, Seiwerth S, Sikiric P. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. J Physiol Pharmacol 2024; 75. [PMID: 38583442 DOI: 10.26402/jpp.2024.1.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Accepted: 02/29/2024] [Indexed: 04/09/2024]
Abstract
Using duodenocolic fistula in rats, this study attempts to highlight the particular cytoprotection aspects of the healing of fistulas and therapy potential of the stable gastric pentadecapeptide BPC 157, a cytoprotection mediator (i.e. upgrading minor vessels to induce healing at both fistula's sides). Upon duodenocolic fistula creation (two 'perforated' lesions put together) (assessed at 3, 6, 9, 12, and 15 min), BPC 157, given locally at the fistula, or intragastrically (10 μg/kg, 10 ng/kg), rapidly induces vessel 'recruitment', 'running' toward the defect, simultaneously at duodenum and colon, providing numerous collaterals and branching. The mRNA expression studies done at that time provided strongly elevated (nitric oxide synthase 2) and decreased (cyclooxygenase-2, vascular endothelial growth factor A, nitric oxide synthase (NOS)-1, NOS-3, nuclear factor-kappa-B-activating protein) gene expression. As therapy, rats with duodenocolic fistulas, received BPC 157 10 μg/kg, 10 ng/kg, per-orally, in drinking water till sacrifice, or alternatively, intraperitoneally, first application at 30 min after surgery, last at 24 h before sacrifice, at day 1, 3, 7, 14, 21, and 28. Controls exhibited both defects persisting, continuous fistula leakage, diarrhea, continuous weight loss, advanced adhesion formation and intestinal obstruction. Contrary, all BPC 157-treated rats have closed both defects, duodenal and colonic, no fistula leakage (finally, maximal instilled volume corresponds to healthy rats), no cachexia, the same weight as before surgery, no diarrhea, markedly less adhesion formation and intestinal passage obstruction. Thus, BPC 157 regimens resolve the duodenal/colon lesions and duodenocolic fistulas in rats, and rapid vessels recovery appears as the essential point in the implementation of the cytoprotection concept in the fistula therapy.
Collapse
Affiliation(s)
- D Vukusic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Zenko Sever
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - M Sever
- Department of Surgery, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - D Drmic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - M Milavic
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - S Sikiric
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - D Rasic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - I Krezic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - S Gojkovic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Prtoric
- Department of Surgery, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - P Bubalo
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - L Coric
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - I Dobric
- Department of Surgery, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Boban Blagaic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - Z Rasic
- Department of Surgery, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Skrtic
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
| | - S Seiwerth
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - P Sikiric
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
| |
Collapse
|
2
|
Bilic Z, Gojkovic S, Kalogjera L, Krezic I, Malekinusic D, Knezevic M, Sever M, Lojo N, Kokot A, Kasnik K, Kralj T, Vukojevic J, Siroglavic M, Peklic M, Drmic D, Milavic M, Sikiric S, Skorak I, Brizic I, Hriberski K, Kubat M, Vladic J, Boban Blagaic A, Tvrdeic A, Skrtic A, Seiwerth S, Sikiric P. Novel insight into Robert's cytoprotection: complex therapeutic effect of cytoprotective pentadecapeptide pentadecapeptide BPC 157 in rats with perforated stomach throughout modulation of nitric oxide-system. Comparison with L-arginine, ranitidine and pantoprazole therapy and L-N G-nitro-L-arginine methyl ester worsening. J Physiol Pharmacol 2021; 72. [PMID: 35485358 DOI: 10.26402/jpp.2021.6.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Accepted: 12/31/2021] [Indexed: 06/14/2023]
Abstract
Surgically perforated stomach (since direct injury in rats until persisting defect and huge adhesions (day 1, day 7)) fairly represent an unresolved cytoprotection issue, and thereby, we focused resolving of the immediate triad, particular vascular failure (vessels 'disappear'/empty), prolonged bleeding, debilitated defect large widening. Agents (mg/kg) or saline (controls) were given at 1 min post-injury as an abdominal bath (10 ml/rat throughout 2 min). Within 1 - 15 min post-injury period, with cytoprotective BPC 157 (0.01 μg), the rapidly restored vessels 'run' (vessels filled/reappeared) toward the perforated defect, and there is less bleeding, and defect contraction; advanced perforated lesion healing (day 1) to complete healing (day 7), and less adhesions. With pantoprazole (10 mg), early (vessels (worsening), bleeding (prolongation), defect (attenuated widening)) effect means eventual lesions and adhesions severity as in controls. Ranitidine (10 mg) early effect (vessels (improvement), bleeding (less bleeding), defect (eliminated widening, defect not changed)) means final lesions attenuation, but not complete healing, less adhesions. L-NAME (5 mg) early (vessels worsening, less bleeding, attenuated defect widening) and final (lesions aggravation, more adhesions) effect, versus L-arginine (100 mg) early (vessels improvement, more bleeding, attenuated defect widening) and final (lesions attenuation, less adhesions) effect, combined few simultaneously occurring nitric oxide (NO)-system distinct processes. Finally, in the stomach tissue surrounding defect, increased malondialdehyde (MDA)- and decreased NO-values, BPC 157 reversed to the normal healthy values, and mRNA expression studies (Cox2, VEGFa, Nos1, Nos 2, Nos3, Nkap (NF-kappa-B-activating protein gene)), done at that very early post-perforation-time, indicate a way how BPC 157 may act beneficially in the perforated stomach lesion throughout NO- and prostaglandinds-system.
Collapse
Affiliation(s)
- Z Bilic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - S Gojkovic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - L Kalogjera
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Krezic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Malekinusic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Knezevic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Sever
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - N Lojo
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Kokot
- Department of Anatomy and Neuroscience, Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - K Kasnik
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - T Kralj
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - J Vukojevic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Siroglavic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Peklic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Drmic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Milavic
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - S Sikiric
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Skorak
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Brizic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - K Hriberski
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - M Kubat
- Department of Forensic Medicine and Criminology, School of Medicne, Zagreb, Croatia
| | - J Vladic
- Laboratory for Advanced Genomics, Division of Molecular Medicine, Institute Ruder Boskovic, Zagreb, Croatia
| | - A Boban Blagaic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Tvrdeic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Skrtic
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.
| | - S Seiwerth
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - P Sikiric
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.
| |
Collapse
|
3
|
Becejac T, Cesarec V, Drmic D, Hirsl D, Madzarac G, Djakovic Z, Bunjevac I, A Zenko Sever A, Sepac A, Batelja Vuletic L, Stancic Rokotov D, Seiwerth S, Sikiric P. An endogeous defensive concept, renewed cytoprotection/adaptive cytoprotection: intra(per)-oral/intragastric strong alcohol in rat. Involvement of pentadecapeptide BPC 157 and nitric oxide system. J Physiol Pharmacol 2018; 69. [PMID: 30279308 DOI: 10.26402/jpp.2018.3.11] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Accepted: 04/30/2018] [Indexed: 11/03/2022]
Abstract
With intra(per)-oral strong alcohol application at the tongue, swallowed, we renewed Robert's stomach cytoprotection/adaptive cytoprotection concept. We assessed strong (96%) alcohol-induced severe or minute lesions in stomach, tongue-esophagus-stomach-duodenum lesions, and sphincter pressure (lower esophageal and pyloric) upon administration intragastrically (at 1 h) or intra(per)-orally at the tongue, and swallowed (at 1, 5, 15, 30 min; and 1, 2, 24 h). The assessment also included combined administrations (intra(per)-oral at the tongue, swallowed and intragastric (at 1 h)). Immediate post-alcohol intraperitoneal medication (mg/kg) was the stable gastric pentadecapeptide BPC 157 (0.01, 0.00001; a Robert's cytoprotection mediator; with a therapeutic effect), NOS-blocker L-NAME (5), and NOS-substrate L-arginine (100 mg), (NO-system involvement). After intragastric strong alcohol administration, severe stomach ulcerations appeared along with widespread tongue, esophagus, duodenum redness, and minimal sphincter pressures. By contrast, a particular syndrome (immediate overlapping of cytoprotection/adaptive cytoprotection) (minute gastric lesion or largely attenuated hemorrhagic ulceration, tongue affected, minute esophageal and duodenal lesions, but with intact mucosa; sphincters pressures lowered) appeared after intra(per)-oral administration (1 min-24 h) as well as after combined administrations (intra(per)-oral + intragastric). BPC 157 apparently cured all alcohol-lesions, amplified the spontaneously initiated strong mucosal beneficial effect, rescued sphincter pressures; NO-agents (L-arginine (slight mucosal amelioration) and L-NAME (aggravation)) showed NO-system involvement, but no comparable effects on dropped sphincters pressures. In conclusion, minute gastric lesions (with oral application of strong alcohol at the tongue and swallowed, without, or with intragastric application of strong alcohol) renew and revise Robert's stomach cytoprotection/adaptive cytoprotection concept. The tongue becomes a new initial target, resulting in spontaneous reversal of strong alcohol-stomach lesions. BPC 157 therapy functions also within the redirected complexity of Robert's stomach cytoprotection/adaptive cytoprotection concept.
Collapse
Affiliation(s)
- T Becejac
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - V Cesarec
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Drmic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Hirsl
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - G Madzarac
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - Z Djakovic
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - I Bunjevac
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A A Zenko Sever
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - A Sepac
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - L Batelja Vuletic
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - D Stancic Rokotov
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - S Seiwerth
- Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia
| | - P Sikiric
- Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.
| |
Collapse
|
4
|
Vitaic S, Stupnisek M, Drmic D, Bauk L, Kokot A, Klicek R, Vcev A, Luetic K, Seiwerth S, Sikiric P. Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats. J Physiol Pharmacol 2017; 68:265-272. [PMID: 28614776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 04/28/2017] [Indexed: 06/07/2023]
Abstract
The sphincters failure is a part of NSAIDs-toxicity that can be accordingly counteracted. We used a safe stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419), LD1 not achieved, since successful in inflammatory bowel disease trials, and counteracts esophagitis, sphincters failure, gastrointestinal ulcer and skin ulcer, external and internal fistulas in rats, and particularly counteracts all NSAIDs-lesions. We assessed lower esophageal sphincter and pyloric sphincter pressure (cmH2O) in rats treated with various NSAIDs regimens, at corresponding time points, known to produce stomach, small intestine lesions, hepatotoxicity and encephalopathy. Assessment was after diclofenac (12.5 mg/kg, 40 mg/kg intraperitoneal challenge), ibuprofen (400 mg/day/kg intraperitoneally for 4 weeks), paracetamol (5.0 g/kg intraperitoneal challenge), aspirin (400 mg/kg intraperitoneally or intragastrically), celecoxib (0.5 mg/kg, 1.0 mg/kg intraperitoneally). BPC 157 (10 μg/kg, 10 ng/kg) was given immediately after NSAIDs (intraperitoneally or intragastrically) or given in drinking water. Regularly, in all control NSAIDs fall of pressure occurred in both sphincters rapidly and then persisted. By contrast, in all NSAIDs-rats that received BPC 157, initial fall of pressure was minimized and pressure values restored to normal values. All tested NSAIDs decrease pressure in both sphincters, whilst BPC 157 counteracts their effects and restored both sphincters function.
Collapse
Affiliation(s)
- S Vitaic
- Medical Faculty J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - M Stupnisek
- Medical Faculty J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - D Drmic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - L Bauk
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Kokot
- Medical Faculty J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - R Klicek
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Vcev
- Medical Faculty J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - K Luetic
- Medical Faculty J.J. Strossmayer University of Osijek, Osijek, Croatia
| | - S Seiwerth
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - P Sikiric
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
| |
Collapse
|
5
|
Skorjanec S, Kokot A, Drmic D, Radic B, Sever M, Klicek R, Kolenc D, Zenko A, Lovric Bencic M, Belosic Halle Z, Situm A, Zivanovic Posilovic G, Masnec S, Suran J, Aralica G, Seiwerth S, Sikiric P. Duodenocutaneous fistula in rats as a model for "wound healing-therapy" in ulcer healing: the effect of pentadecapeptide BPC 157, L-nitro-arginine methyl ester and L-arginine. J Physiol Pharmacol 2015; 66:581-590. [PMID: 26348082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/11/2014] [Accepted: 05/08/2015] [Indexed: 06/05/2023]
Abstract
While very rarely reported, duodenocutanenous fistula research might alter the duodenal ulcer disease background and therapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, an anti-ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L-arginine, and nitric oxide synthase-inhibitor L-nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, using the successful BPC 157, with nitric oxide-system involvement, the "wound healing-therapy", to heal the duodenal ulcer, the fistula-model that recently highlighted gastric and skin ulcer healing. Pressure in the lower esophageal and pyloric sphincters was simultaneously assessed. Duodenocutaneous fistula-rats received BPC 157 (10 μg/kg or 10 ng/kg, intraperitoneally or perorally (in drinking water)), L-NAME (5 mg/kg intraperitoneally), L-arginine (100 mg/kg intraperitoneally) alone and/or together, throughout 21 days. Duodenocutaneous fistula-rats maintained persistent defects, continuous fistula leakage, sphincter failure, mortality rate at 40% until the 4(th) day, all fully counteracted in all BPC 157-rats. The BPC 157-rats experienced rapidly improved complete presentation (maximal volume instilled already at 7(th) day). L-NAME further aggravated the duodenocutaneous fistula-course (mortality at 70% until the 4(th) day); L-arginine was beneficial (no mortality; however, maximal volume instilled not before 21(st) day). L-NAME-worsening was counteracted to the control level with the L-arginine effect, and vice versa, while BPC 157 annulled the L-NAME effects (L-NAME + L-arginine; L-NAME + BPC 157; L-NAME + L-arginine + BPC 157 brought below the level of the control). It is likely that duodenocutaneous fistulas, duodenal/skin defect simultaneous healing, reinstated sphincter function, are a new nitric oxide-system related phenomenon. In conclusion, resolving the duodenocutanenous fistulashealing, nitric oxide-system involvement, should illustrate further wound healing therapy to heal duodenal ulcers.
Collapse
Affiliation(s)
- S Skorjanec
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Kokot
- Department of Anatomy and Neuroscience, Medical Faculty, J.J Strossmayer University of Osijek, Osijek, Croatia
| | - D Drmic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - B Radic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - M Sever
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - R Klicek
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - D Kolenc
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Zenko
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - M Lovric Bencic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - Z Belosic Halle
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - A Situm
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | | | - S Masnec
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - J Suran
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - G Aralica
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - S Seiwerth
- Department of Pathology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | - P Sikiric
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
| |
Collapse
|
6
|
Klicek R, Kolenc D, Suran J, Drmic D, Brcic L, Aralica G, Sever M, Holjevac J, Radic B, Turudic T, Kokot A, Patrlj L, Rucman R, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol 2013; 64:597-612. [PMID: 24304574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 12/10/2012] [Accepted: 09/16/2013] [Indexed: 06/02/2023]
Abstract
Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline (5 ml/kg) intraperitoneally or drinking water only (12 ml/day). A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4. In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time. Likewise, cuprizone-controls clearly exhibited an exaggerated and accelerated damaging process; nerve damage appeared in various brain areas, with most prominent damage in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons. BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected. Consistently, BPC 157 counteracted cerebellar ataxia and impaired forelimb function. Thereby, this experimental evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy.
Collapse
Affiliation(s)
- R Klicek
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Stambolija V, Zoricic Z, Vrcic H, Sebecic B. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem 2012; 19:126-32. [PMID: 22300085 DOI: 10.2174/092986712803414015] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Revised: 11/04/2011] [Accepted: 11/07/2011] [Indexed: 12/18/2022]
Abstract
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1-A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157's high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis.
Collapse
Affiliation(s)
- P Sikiric
- Department of Pharmacology, Medical Faculty University of Zagreb, Salata 11, POB 916, 10000 Zagreb, Croatia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Petrovic I, Dobric I, Drmic D, Sever M, Klicek R, Radic B, Brcic L, Kolenc D, Zlatar M, Kunjko K, Jurcic D, Martinac M, Rasic Z, Boban Blagaic A, Romic Z, Seiwerth S, Sikiric P. BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure. J Physiol Pharmacol 2011; 62:527-534. [PMID: 22204800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/11/2011] [Accepted: 10/03/2011] [Indexed: 05/31/2023]
Abstract
Possibly, acute esophagitis and pancreatitis cause each other, and we focused on sphincteric failure as the common causative key able to induce either esophagitis and acute pancreatitis or both of them, and thereby investigate the presence of a common therapy nominator. This may be an anti-ulcer pentadecapeptide BPC 157 (tested for inflammatory bowel disease, wound treatment) affecting esophagitis, lower esophageal and pyloric sphincters failure and acute pancreatitis (10 μg/kg, 10 ng/kg intraperitoneally or in drinking water). The esophagitis-sphincter failure procedure (i.e., insertion of the tubes into the sphincters, lower esophageal and pyloric) and acute pancreatitis procedure (i.e., bile duct ligation) were combined in rats. Esophageal manometry was done in acute pancreatitis patients. In rats acute pancreatitis procedure produced also esophagitis and both sphincter failure, decreased pressure 24 h post-surgery. Furthermore, bile duct ligation alone immediately declines the pressure in both sphincters. Vice versa, the esophagitis-sphincter failure procedure alone produced acute pancreatitis. What's more, these lesions (esophagitis, sphincter failure, acute pancreatitis when combined) aggravate each other (tubes into sphincters and ligated bile duct). Counteraction occurred by BPC 157 therapies. In acute pancreatitis patients lower pressure at rest was in both esophageal sphincters in acute pancreatitis patients. We conclude that BPC 157 could cure esophagitis/sphincter/acute pancreatitis healing failure.
Collapse
Affiliation(s)
- I Petrovic
- Department of Pharmacology, Medical Faculty, University of Zagreb, Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ilic S, Drmic D, Zarkovic K, Kolenc D, Coric M, Brcic L, Klicek R, Radic B, Sever M, Djuzel V, Ivica M, Boban Blagaic A, Zoricic Z, Anic T, Zoricic I, Djidic S, Romic Z, Seiwerth S, Sikiric P. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats. A counteraction with the stable gastric pentadecapeptide BPC 157 (PL 14736). J Physiol Pharmacol 2010; 61:241-250. [PMID: 20436226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/10/2009] [Accepted: 03/19/2010] [Indexed: 05/29/2023]
Abstract
We focused on stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported) because of its hepatoprotective effects. We investigate a particular aspect of the sudden onset of encephalopathy with extreme paracetamol overdose (5 g/kg intraperitoneally) so far not reported: rapidly induced progressive hepatic encephalopathy with generalized convulsions in rats. BPC 157 therapy (10 microg, 10 ng, 10 pg/kg, intraperitoneally or intragastrically) was effective (microg-ng range) against paracetamol toxicity, given in early (BPC 157 immediately after paracetamol, prophylactically) or advanced stage (BPC 157 at 3 hours after paracetamol, therapeutically). At 25 min post-paracetamol increased ALT, AST and ammonium serum values precede liver lesion while in several brain areas, significant damage became apparent, accompanied by generalized convulsions. Through the next 5 hour seizure period and thereafter, the brain damage, liver damage enzyme values and hyperammonemia increased, particularly throughout the 3-24 h post-paracetamol period. BPC 157 demonstrated clinical (no convulsions (prophylactic application) or convulsions rapidly disappeared (therapeutic effect within 25 min)), microscopical (markedly less liver and brain lesions) and biochemical (enzyme and ammonium serum levels decreased) counteraction. Both, the prophylactic and therapeutic benefits (intraperitoneally and intragastrically) clearly imply BPC 157 (microg-ng range) as a highly effective paracetamol antidote even against highly advanced damaging processes induced by an extreme paracetamol over-dose.
Collapse
Affiliation(s)
- S Ilic
- Department of Pharmacology and Pathology, Medical Faculty University of Zagreb, Zagreb, Croatia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|